Oral nadolol feasible for the treatment of infantile hemangiomas

Oral nadolol feasible for the treatment of infantile hemangiomas

(HealthDay)—Nadolol may be a safe and efficacious alternative for the treatment of infantile hemangiomas in infants who experience unresponsiveness or adverse events to propranolol, according to a study published online Nov. 8 in JAMA Pediatrics.

Elena Pope, M.D., from The Hospital for Sick Children at the University of Toronto, and colleagues compared oral propranolol with oral in infants aged 1 to 6 months with problematic infantile hemangioma. The analysis included 71 with hemangioma >1.5 cm on the face or ≥3 cm on another body part causing, or with potential to cause, functional impairment or cosmetic disfigurement.

The researchers found that the difference in infantile hemangioma between groups by t test was 8.8 for size and 17.1 for color in favor of the nadolol group, demonstrating that nadolol was noninferior to propranolol. At 52 weeks, results were similar (6.0 for size and 10.1 for color improvement). The coefficient of involution was 2.4 higher with nadolol versus propranolol for each doubling of time unit (week). Safety data were similar between the groups.

“Oral nadolol was noninferior to oral propranolol, indicating it may be an efficacious and safe alternative in cases of propranolol unresponsiveness or adverse events, or when faster involution is required,” the authors write.

Several authors disclosed financial ties to the .

Oral propranolol seems safe for infantile hemangioma

More information:
Abstract/Full Text

Copyright © 2021 HealthDay. All rights reserved.

Oral nadolol feasible for the treatment of infantile hemangiomas (2021, November 10)
retrieved 10 November 2021
from https://medicalxpress.com/news/2021-11-oral-nadolol-feasible-treatment-infantile.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Source link

Leave a Reply